OMIC 21.37 Stock Price Singular Genomics Systems, Inc.
Range: | 5.34-23.41 | Vol Avg: | 107450 | Last Div: | 0 | Changes: | 0.02 |
Beta: | 1.51 | Cap: | 0.05B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Thu May 27 2021 | Empoloyees: | 255 |
CUSIP: | 82933R100 | CIK: | 0001850906 | ISIN: | US82933R1005 | Country: | US |
CEO: | Mr. Andrew Spaventa | Website: | https://singulargenomics.com |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.